Commentary
Video
Author(s):
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Five Under 5: Top Oncology Videos for the Week of 1/26
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Nivolumab/Ipilimumab Approaches EU Approval in Unresectable or Advanced HCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
T-DM1 Is Not Associated With Improved PFS vs Historical Controls in Pretreated HER2+ Biliary Tract Cancer
FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
CHMP Recommends Approval of Durvalumab for Limited-Stage Small Cell Lung Cancer
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC
FDA Approves Companion Diagnostic for T-DXd in HER2-Ultralow Metastatic Breast Cancer